HIMS Form 4: Oluyemi Okupe exercised options and sold shares under 10b5-1 plan
Rhea-AI Filing Summary
Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (HIMS), executed option exercises and share sales under a Rule 10b5-1 plan on 09/29/2025. He exercised 49,832 stock options with a $5.01 exercise price and sold 85,000 Class A common shares at a weighted average price of $60.1991 (sales ranged $59.95–$60.48). Following the reported transactions, the filing shows 70,232 shares directly beneficially owned and 7,853 shares indirectly held by the Oluyemi Okupe Separate Property Trust dated 9-1-2021. The filing discloses remaining derivative holdings totaling 189,952 option shares following the transactions and notes vesting terms and the 10b5-1 plan adoption date of May 21, 2025.
Positive
- Transactions were executed under a Rule 10b5-1 trading plan, which provides pre-established parameters and transparency
- Sales reported with a weighted average price ($60.1991) and price range ($59.95–$60.48), giving clear pricing information
- Filing includes vesting schedule and trust-held shares, improving disclosure of continued insider economic interest
Negative
- Reported sale of 85,000 shares represents a sizable insider disposition (no gross proceeds disclosed in the form)
- Filing does not state gross proceeds from the sales, requiring third-party calculation if needed
Insights
TL;DR: Routine insider exercise and sale under a 10b5-1 plan; proceeds realized at ~ $60.20 per share.
The transaction is a common liquidity event for executives who exercise low-cost options and monetize shares. Exercising 49,832 options at a $5.01 strike and selling 85,000 shares at a weighted average of $60.1991 generated material proceeds relative to the option strike but the filing does not disclose gross proceeds. The use of a pre-established Rule 10b5-1 plan and explicit sale price range reduces concerns about opportunistic timing. The remaining direct and indirect holdings, plus 189,952 derivative shares, indicate continued economic exposure to company equity.
TL;DR: Disclosure conforms to standard reporting; transactions were executed under a documented 10b5-1 plan.
The Form 4 properly reports exercise, sale, and beneficial ownership changes and includes the 10b5-1 adoption date and sale price range. The filing also provides vesting schedule details for outstanding options and identifies indirect ownership via a trust. There are no stated amendments or caveats; on-file signatures and attorney-in-fact execution satisfy procedural requirements. This is a routine, transparent insider disclosure with no filing irregularities disclosed.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 49,832 | $0.00 | -- |
| Exercise | Class A Common Stock | 49,832 | $5.01 | $250K |
| Sale | Class A Common Stock | 85,000 | $60.1991 | $5.12M |
| holding | Class A Common Stock | -- | -- | -- |
Footnotes (1)
- The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025 by the Reporting Person. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $59.95 - $60.48. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. 25% of the options will vest on the twelve (12) month anniversary of the Vesting Commencement Date of January 24, 2022. The balance of the shares shall vest in a series of thirty-six (36) successive equal monthly installments measured from the twelve (12) month anniversary of the Vesting Commencement Date, subject to optionholder's continuous Service (as defined in the Plan) as of each such vesting date.
